Internal Medicine, Hematology & Oncology · Newark, DE
NPI
1174665822
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
4701 Ogletown Stanton Rd, Suite 3400
Newark, DE, 19713
Phone (302) 366-1200
Groups this clinician bills Medicare through
Medicare paid, 2024
$11.0M
550,501 services
Medicare patients, 2024
822
Average age 75
Drug cost, 2024
$9.1M
2,585 prescriptions
Company payments, 2025
$2,086
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jamal G Misleh was code J9271 (injection, pembrolizumab, 1 mg), 46,000 times for 37 patients. In total Jamal G Misleh billed 550,501 services in 146 codes, and Medicare paid $11.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-06-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 46,000 | 37 | $44.67 | $2.1M |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 39,600 | 32 | $39.26 | $1.6M |
| J0896 Injection, luspatercept-aamt, 0.25 mg | Office | 39,448 | 12 | $31.61 | $1.2M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 21,835 | 24 | $2.33 | $51K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 21,800 | 16 | $0.06 | $1,204 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 17,820 | 30 | $35.99 | $641K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 14,916 | 36 | $20.38 | $304K |
| J0897 Injection, denosumab, 1 mg | Office | 12,840 | 48 | $20.48 | $263K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 10,800 | 76 | $15.70 | $170K |
| J9312 Injection, rituximab, 10 mg | Office | 7,950 | 23 | $61.45 | $489K |
| J9041 Injection, bortezomib, 0.1 mg | Office | 6,850 | 16 | $1.41 | $9,668 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 6,455 | 117 | $0.09 | $562 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,844 | 26 | $0.69 | $1,966 |
| J9267 Injection, paclitaxel, 1 mg | Office | 1,912 | 11 | $0.07 | $140 |
| J3480 Injection, potassium chloride, per 2 meq | Office | 1,540 | 33 | $0.08 | $129 |
By year: 2022 $10.9M for 700,023 services; 2023 $10.4M for 590,958 services; 2024 $11.0M for 550,501 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 23 | 17 | $8.40 | $193 |
Medicare prescription drug claims, 2024
In 2024, the drug Jamal G Misleh prescribed most often to Medicare patients was Acyclovir, with 325 prescriptions and refills. In total Jamal G Misleh wrote 2,585 Medicare prescriptions that cost $9.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 325 | 500 | 73 | $6,038 |
| Prednisone Generic | 168 | 206 | 45 | $794 |
| Lenalidomide Generic | 135 | 135 | 20 | $2.1M |
| Eliquis Apixaban | 101 | 151 | 26 | $86K |
| Gabapentin Generic | 98 | 162 | 25 | $1,938 |
| Allopurinol Generic | 85 | 173 | 30 | $556 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 82 | 106 | 25 | $273 |
| Imbruvica Ibrutinib | 75 | 75 | Under 11 | $1.2M |
| Anastrozole Generic | 71 | 189 | 25 | $3,137 |
| Prochlorperazine Maleate Generic | 66 | 66 | 48 | $677 |
| Xarelto Rivaroxaban | 58 | 82 | Under 11 | $45K |
| Potassium Chloride Generic | 49 | 96 | 18 | $487 |
| Hydroxyurea Generic | 49 | 71 | Under 11 | $603 |
| Levothyroxine Sodium Generic | 49 | 99 | 13 | $494 |
| Dexamethasone Generic | 45 | 49 | 25 | $683 |
Brand drugs: - claims; generic drugs: 1,962 claims; opioid claims: 56.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jamal G Misleh $2,086 ($563 in general payments such as food, travel and fees and $1,524 for research) from 29 companies. The largest payer was F. Hoffmann-La Roche AG with $1,524.
| Company | Payments | Amount |
|---|---|---|
| F. Hoffmann-La Roche AG ROG.SW | 2 | $1,524 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $92.9 |
| Regeneron Healthcare Solutions, Inc. REGN | 1 | $78 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $45.44 |
| Incyte Corporation INCY | 2 | $38.18 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $36.59 |
| Azurity Pharmaceuticals, Inc. | 1 | $31.33 |
| Celgene Corporation BMY | 1 | $28.57 |
| Geron Corporation GERN | 1 | $25.79 |
| Genmab U.S., Inc. GMAB | 1 | $24.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.